AngioFlow Thermodilution System

	AngioDynamics, Inc.	
PHONE	(800) 772-6446, ext. 167	
WEB	www.angiodynamics.com	

KEY FEATURES

- Real-time blood flow measurement during diagnostic and therapeutic endovascular procedures intended to maintain patency of a hemodialysis graft/fistula
- Provides immediate information useful for the detection of inconspicuous lesions

AngioDynamics, Inc.'s (Queensbury, NY), patented AngioFlow Thermodilution Catheter and Meter System is used to quantify blood flow during diagnostic and therapeutic endovascular procedures. This system meas-



ures blood flow within a vascular bed utilizing a catheter-based sensor. Thermal changes induced by a bolus injection of normal saline are analyzed using thermal-dilution principles to calculate blood flow.

The company comments that maintaining patency of a vascular access graft/fistula is critical to the survival of chronic renal failure patients. Several studies show blood flow <600 mL/min is predictive of a developing stenosis within a graft/fistula. If left untreated, occlusion will occur, preventing a patient from undergoing hemodialysis. Multiple endovascular and surgical interventions are often required to maintain patency of a vascular access. The AngioFlow system provides accurate and immediate blood flow measurements during the first intervention, states AngioDynamics.

Sprinter Balloon Dilatation Catheter

COMPANY	Medtronic, Inc.
PHONE	(888) 283-7868
WEB	www.medtronic.com
-	

KEY FEATURES

- · Low lesion-entry profile (.016 inch)
- Automated MiniWrap folding process allows for tight wrap of balloon on catheter and multiple inflations
- Dura-Trac Coating provides performance of a fully coated balloon while tracking through tortuous vessels

After receiving FDA approval in July, Medtronic, Inc. (Santa Rosa, CA), has launched its Sprinter Semi-Compliant Over-the-Wire Balloon Dilatation Catheter in the US. The device is now available in lengths of 6 mm, 12 mm, 15 mm, 20 mm, 25 mm, and 30 mm and diameters ranging from 1.5 mm to 4 mm.



According to the company, the Sprinter's lesion-entry profile is .016 inch, and its MiniWrap Folding Process provides for an extremely tight wrap of the balloon on the catheter and incorporates rewrap properties for multiple inflations. The device is coated with Selective Dura-Trac Coating after it is folded, providing the performance of a fully coated balloon while tracking through tortuous vessels. The material inside the folds is uncoated, which provides traction upon expansion in the lesion.

Allura Xper FD20

COMPANY	Philips Medical Systems
PHONE	+0031 40 27 64293
WEB	www.medical.philips.com/allura

KEY FEATURES

- Image quality through 2k² imaging chain
- Workflow efficiency with Xper technology
- · Ready for future applications
- · Enhanced patient safety
- Proprietary DoseWise technology ensures lowest possible radiation dose

Philips Medical Systems (Best, The Netherlands) has introduced the Allura Xper FD20. The Allura Xper FD20 flat detector's complete 2,048 X 2,048 pixel, distortion-free imaging chain provides image clarity with 154-µm pixels for higher resolution and contrast visualization. It is adjustable from



30 cm X 40 cm up to 16 cm². The company states that the Allura FD series includes several key safety features, including the high-performance MRC x-ray in combination with SpectraBeam copper filtration system, which captures and filters out harmful low-energy x-rays. Exclusive to the Allura FD series, BodyGuard, a highly sensitive electromagnetic field, further enhances safety by sensing objects, patients, and technicians.

CLiRpath Excimer Laser Catheters for PAD


COMPANY	Spectranetics Corporation
PHONE	(800) 231-0978
WEB	www.spectranetics.com

KEY FEATURES

- CLiRpath catheters use cool ultraviolet excimer laser energy to cross total occlusions refractory to a guidewire in peripheral arteries
- Available in sizes from 0.9 mm to 2.5 mm in diameter
- OTW and Rx configurations compatible with 0.014-, 0.018-, and 0.035-inch guidewires

Spectranetics Corporation (Colorado Springs, CO) recently received 510(k) market clearance to treat patients suffering from total occlusions in peripheral arteries with proprietary Spectranetics' excimer laser catheters. The market clearance, which was based on a review of clinical data from a subset of patients enrolled in the LACI trial, applies to most of the company's coronary catheters ranging in diameter from .9 mm to 2 mm. In addition, five new catheters, ranging in size from 2 mm to 2.5 mm that are specifically designed for treating blockages in peripheral arteries, were included in the 510(k) market release.

Used in conjunction with the CVX-300 Excimer Laser System, CLiRpath catheters use cool ultravio-



let excimer laser energy to vaporize atheromatous material and restore straightline blood flow to the foot. The CLiRpath system vaporizes plaque and thrombus by safely delivering high energy in extremely short pulses. The catheters ablate tissue on contact without inducing thermal damage to treated artery. The CVX-300 excimer laser has been safely and effectively used to treat coronary artery disease in over 20,000 patients since 1993, the company reports.